ImageneBio (IMA) Competitors $13.80 -0.24 (-1.71%) As of 02:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMA vs. TVRD, ALLO, VOR, AARD, OGI, AVTE, CRGX, ACIU, ALEC, and SOPHShould you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Tvardi Therapeutics (TVRD), Allogene Therapeutics (ALLO), Vor Biopharma (VOR), Aardvark Therapeutics (AARD), Organigram Global (OGI), Aerovate Therapeutics (AVTE), CARGO Therapeutics (CRGX), AC Immune (ACIU), Alector (ALEC), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. ImageneBio vs. Its Competitors Tvardi Therapeutics Allogene Therapeutics Vor Biopharma Aardvark Therapeutics Organigram Global Aerovate Therapeutics CARGO Therapeutics AC Immune Alector SOPHiA GENETICS ImageneBio (NASDAQ:IMA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Which has more volatility and risk, IMA or TVRD? ImageneBio has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Does the media refer more to IMA or TVRD? In the previous week, Tvardi Therapeutics had 6 more articles in the media than ImageneBio. MarketBeat recorded 6 mentions for Tvardi Therapeutics and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 beat Tvardi Therapeutics' score of -0.74 indicating that ImageneBio is being referred to more favorably in the media. Company Overall Sentiment ImageneBio Neutral Tvardi Therapeutics Negative Is IMA or TVRD more profitable? ImageneBio has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -595.39%. ImageneBio's return on equity of -23.94% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImageneBioN/A -23.94% -21.62% Tvardi Therapeutics -595.39%-565.83%-66.71% Do institutionals & insiders have more ownership in IMA or TVRD? 75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer IMA or TVRD? ImageneBio currently has a consensus target price of $35.50, indicating a potential upside of 157.25%. Tvardi Therapeutics has a consensus target price of $64.25, indicating a potential upside of 146.07%. Given ImageneBio's higher possible upside, equities analysts clearly believe ImageneBio is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, IMA or TVRD? ImageneBio has higher revenue and earnings than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImageneBio$9.16M6.06-$49.23M-$7.68-1.80Tvardi Therapeutics$7.14M34.30-$70.87MN/AN/A SummaryImageneBio beats Tvardi Therapeutics on 10 of the 14 factors compared between the two stocks. Get ImageneBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMA vs. The Competition Export to ExcelMetricImageneBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.48M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-1.8020.4630.4325.11Price / Sales6.06237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book0.487.959.016.20Net Income-$49.23M-$54.72M$3.26B$265.38M7 Day Performance-6.69%1.56%1.00%-1.25%1 Month Performance-9.45%5.71%4.19%-0.81%1 Year Performance-33.53%9.01%28.39%18.83% ImageneBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMAImageneBio2.5387 of 5 stars$13.80-1.7%$35.50+157.2%-31.6%$55.48M$9.16M-1.8070TVRDTvardi Therapeutics1.2792 of 5 stars$23.80-1.4%$64.25+170.0%N/A$222.77M$7.14M0.0080News CoveragePositive NewsEarnings ReportGap DownALLOAllogene Therapeutics3.0017 of 5 stars$1.02-1.5%$8.44+732.0%-59.8%$222.01M$20K-0.83310Analyst RevisionVORVor Biopharma2.0017 of 5 stars$1.74-12.8%$5.63+224.4%+122.2%$220.98MN/A-1.06140Analyst RevisionAARDAardvark TherapeuticsN/A$10.14-9.1%$33.00+225.4%N/A$220.04MN/A0.0018Trending NewsAnalyst RevisionOGIOrganigram Global0.4037 of 5 stars$1.64-0.3%N/A-21.9%$219.14M$117.47M16.35860Analyst RevisionAVTEAerovate TherapeuticsN/A$7.49+2.3%N/A-88.4%$217.10MN/A-2.5120High Trading VolumeCRGXCARGO Therapeutics2.0577 of 5 stars$4.47-0.3%$15.40+244.9%N/A$215.93MN/A-0.96116ACIUAC Immune1.715 of 5 stars$2.14+3.4%$12.00+460.7%-36.7%$215.18M$31.02M-3.69140Positive NewsALECAlector3.6161 of 5 stars$2.09-6.5%$4.17+99.8%-57.8%$211.02M$100.56M-1.80270SOPHSOPHiA GENETICS2.8472 of 5 stars$3.05+1.2%$8.00+162.7%-3.2%$205.78M$65.17M-6.92520Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies TVRD Competitors ALLO Competitors VOR Competitors AARD Competitors OGI Competitors AVTE Competitors CRGX Competitors ACIU Competitors ALEC Competitors SOPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access